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Abstract
Introduction: Rheumatoid arthritis (RA) is a chronic disease associated with inflammation and destruction of bone
and cartilage. Although inhibition of TNFa is widely used to treat RA, a significant number of patients do not
respond to TNFa blockade, and therefore there is a compelling need to continue to identify alternative therapeutic
strategies for treating chronic inflammatory diseases such as RA. The anti-epidermal growth factor (anti-EGF)
receptor antibody trastuzumab has revolutionised the treatment of patients with EGF receptor-positive breast
cancer. Expression of EGF ligands and receptors (known as HER) has also been documented in RA. The highly
unique compound RB200 is a bispecific ligand trap that is composed of full-length extracellular domains of HER1
and HER3 EGF receptors. Because of its pan-HER specificity, RB200 inhibits responses mediated by HER1, HER2 and
HER3 in vitro and in vivo. The objective of this study was to assess the effect of RB200 combined with TNF
blockade in a murine collagen-induced arthritis (CIA) model of RA.
Methods: Arthritic mice were treated with RB200 alone or in combination with the TNF receptor fusion protein
etanercept. We performed immunohistochemistry to assess CD31 and in vivo fluorescent imaging using anti-E-
selectin antibody labelled with fluorescent dye to elucidate the effect of RB200 on the vasculature in CIA.
Results: RB200 significantly abrogated CIA by reducing paw swelling and clinical scores. Importantly, low-dose
RB200 combined with a suboptimal dose of etanercept led to complete abrogation of arthritis. Moreover, the
combination of RB200 with etanercept abrogated the intensity of the E-selectin-targeted signal to the level seen in
control animals not immunised to CIA.
Conclusions: The human pan-EGF receptor bispecific ligand trap RB200, when combined with low-dose
etanercept, abrogates CIA, suggesting that inhibition of events downstream of EGF receptor activation, in
combination with TNFa inhibitors, may hold promise as a future therapy for patients with RA.
Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune dis-
order characterised by severe synovial inflammation that
leads to the progressive destruction of bone and carti-
lage. It is a severe disabling disease that affects approxi-
mately 1% of the population worldwide [1]. Despite the
introduction of biological t h e r a p i e ss u c ha st h o s et h a t
target TNFa, a significant proportion of RA patients do
n o td e m o n s t r a t eap o s i t i v er e s p o n s et ot r e a t m e n t .
Furthermore, biologicals such as TNFa are associated
with increased risk of serious infections, including tuber-
culosis [2-5]. In addition, the pattern of disease in
patients may change over time and alternative or addi-
tional therapy may be required.
The epidermal growth factor (EGF) ligand/receptor
family has been postulated to play a role in RA
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epidermal growth factor receptor (HER)) of cell-surface
receptors belong to the receptor tyrosine kinase (RTK)
superfamily and consist of extracellular domains (ECDs)
and an intracellular tyrosine kinase signalling domain
[7,8]. The EGF family has four members, namely, EGF
receptor (EGFR)/HER1/ErbB1, HER2/ErbB2, HER3/
ErbB3 and HER4/ErbB4, which are activated by a large
family of ligands, including EGF, as well as by trans-
forming growth factor a (TGF-a), heparin-binding EGF-
like growth factor (HB-EGF), amphiregulin (AR), b-cel-
lulin (BTC), epiregulin (EPR), epigen (EPG) and neure-
gulin (NRG) [7,9,10]. Within the EGFRs there are four
ECDs, with domains I and III being ligand-binding
domains and domains II and IV mediating binding to
each other and to other members of this receptor
family. Ligand binding induces the formation of homo-
or heterodimers between the receptors. For example,
TGF-a and EGF bind to EGFR/HER1/ErbB1, whereas
NRG4 binds to HER4/ErbB4. Depending on the dimer
formed, transphosphorylation of intracellular regions
occurs, leading to the activation of numerous down-
stream signalling pathways, which results in cell prolif-
eration, survival and differentiation [7,9,10]. Researchers
in a number of studies have suggested that the EGF
ligand/receptor family has a role in the development of
inflammatory arthritis [11-14]. In addition to the pre-
sence of EGF in RA synovium [6], expression of HER2/
ErbB2 has been reported [12]. Other EGFR ligands in
addition to EGF have been detected, namely, TGF-a
and AR [11,15].
A number of agents targeting EGFRs have been suc-
cessfully developed for the treatment of cancer. The first
approved HER therapeutic drug, trastuzumab, is a
monoclonal antibody that targets HER2 and has revolu-
tionised the treatment of HER2-overexpressing, node-
positive or node-negative breast cancer [16]. Cetuximab
is a monoclonal antibody that targets HER1 and is pre-
scribed for patients with metastatic colorectal cancer as
well as for those with head and neck cancer. Similarly,
panitumumab (mAb) is a fully human anti-HER1 anti-
body used for the treatment of metastatic colorectal
cancer. In contrast, lapatinib is a RTK inhibitor which
interrupts EGFR/HER1 and HER2/ErbB2 signalling and
has been approved as a frontline therapy for triple-posi-
tive breast cancer and as an adjuvant therapy for
patients who have progressed on trastuzumab. Erlotinib
is used to treat non-small cell lung cancer and pancrea-
tic cancer and is a RTK inhibitor targeting EGFR/HER1.
Several other drugs targeting HER1, HER2 and HER3
are currently in development [17]. However, resistance
to agents that target single HER family members can
occur as a result of compensation by or upregulation of
other HER family members [10]. Furthermore, the
homodimerisation and heterodimerisation among mem-
bers of the HER/ErbB family of receptors has implica-
tions for therapies directed against a single HER
receptor [7].
The antagonist RB200 has been developed to target all
four members of the EGFR family. RB200 is composed of
the ECD of HER1/ErbB1 (amino acids 1 to 621) and
HER3/ErbB3 (amino acids 1 to 621), fused with the Fc
domain of human immunoglobulin G1 (IgG1) (HER1-
HER3/Fc), and acts as a chimeric bispecific ligand trap.
The HER3/Fc component of RB200 contains a 6×Histi-
dine tag on the COOH terminal [18,19]. RB200 has been
shown to bind both HER1/ErbB1 ligands (EGF, TGF-a,
HB-EGF, AR, BTC, EPR and EPG) and HER3/ErbB3
ligands (NRG1-a and NRG1-b3) with high affinity.
Moreover, RB200 inhibited EGF-stimulated and NRG1-
b1-stimulated tyrosine phosphorylation of HER family
proteins (HER1, HER2 and HER3) in vitro and has
shown potency in a variety of cell proliferation assays
[18]. In addition, RB200 has been shown to inhibit
tumour growth in vivo in two human xenograft (epider-
moid carcinoma and non-small cell lung cancer) nude
mouse models [18]. In parallel with these findings, we
have shown that adenoviral delivery of a human EGFR
family inhibitor, herstatin, significantly abrogated all clin-
ical signs of collagen-induced arthritis (CIA) in mice [20].
Herstatin is an alternative splice variant of HER2/ErbB2
that retains intron 8, which results in the formation of an
approximately 68 kDa protein. This protein disrupts
dimerisation and serves as a natural inhibitor of native
HER2/ErbB2 as well as HER1/ErbB1 and HER3/ErbB3
[21]. Thus, in addition to being well-validated targets for
cancer therapy, HER-targeted treatments may have thera-
peutic potential across a range of autoimmune and
inflammatory conditions, including RA.
In the present study, we explored the therapeutic
effects of RB200 in combination with the TNFa inhibitor
etanercept in murine CIA as a model of human RA. Our
data demonstrate that RB200 potently reduced all mea-
sures of arthritis in CIA. Furthermore, when low-dose
RB200 and etanercept were combined, there was com-
plete abrogation of CIA. This was confirmed on the basis
of in vivo E-selectin-targeted fluorescence imaging, which
is a novel technique that we have shown can detect
endothelial activation in CIA and delineate subclinical
arthritis [22]. These data suggest that targeting EGFR-
mediated responses in combination with TNFa may pro-
vide additional clinical benefit in patients with RA.
Materials and methods
Induction and assessment of arthritis
Type II collagen was extracted from bovine articular
cartilage as previously described [19,20,23]. For induc-
tion of CIA, 12-week-old male DBA/1 (H-2
q)m i c e
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mal injection at the base of the tail of 100 μgo fb o v i n e
type II collagen emulsified in complete Freund’sa d j u -
vant and Mycobacterium tuberculosis H37 Ra (Difco
Becton Dickinson, Cowley, Oxford, UK). The animal
work was conducted under Home Office Project Licence
PPL 70/5446, ‘Pathogenesis and therapy for RA’,u n d e r
the operatives of the Animals (Scientific Procedures)
Act 1986.
The incidence of arthritis in each group of animals
reached at least 80%. The earliest signs of disease were
observed on day 14 after immunisation, with day 27
postimmunisation being the median day of arthritis
onset. The first clinical signs of arthritis were considered
to be present when oedema and/or erythema involving
any one of the four paws was observed. Human TNF
type II receptor fusion protein (etanercept) was obtained
from Wyeth Pharmaceuticals, Taplow, UK, and RB200
was a gift from Dr Michael Shepard (Halozyme Thera-
peutics, San Diego, CA, USA). Control animals received
equivalent volumes of PBS. The mice were treated intra-
peritoneally on the day of disease onset (day 1) and then
on days 4 and 7 of disease with RB200 at the indicated
doses. Control mice received intraperitoneal injections
of either etanercept or equivalent volumes of PBS. The
study involved four comparable experiments to test the
efficacy of different doses of RB200. All treatments were
administered in a blinded fashion.
Paw swelling was measured with 0- to 10-mm calli-
pers (Kroeplin, Schluchern, Germany). Each limb was
further assigned a clinical score as follows: 0 = normal
paws and no clinical features of inflammation, 1 = slight
oedema or erythema, 2 = pervading oedema or erythema
involving the entire paw and 3 = pronounced oedema
and erythema leading to incapacitated limb mobility.
Histological analysis
Hind paws were removed postmortem and sliced along
the sagittal plane prior to fixation with 1% paraformal-
dehyde. Paws were decalcified for 14 days in 0.3 M ethy-
lenediaminetetraacetic acid, and CD31 expression was
examined by immunohistochemistry using anti-mouse
CD31 antibody (MEC13.3 rat anti-mouse mAb; Phar-
mingen, San Diego, CA, USA). The sections were then
incubated with biotinylated rabbit anti-rat antibody
(1:400 dilution; Dako, Ely, UK), followed by avidin-bio-
tin-peroxidase complex and diaminobenzidine-H2O2.
Immunostained sections were counterstained with Har-
ris’s haematoxylin. As a negative control, rat IgG2a anti-
body was used (R35-95; Pharmingen). Scores were
graded in a blinded fashion, and the criteria assessed
were (1) proximity of CD31 staining to the joint, (2)
strength of CD31 staining, (3) degree of infiltration of
synovial cells into the joint and (4) overall status of joint
architecture. Sections were further stained with haema-
t o x y l i na n de o s i na sw e l la sw i t ht o l u i d i n eb l u e .E a c h
stained section was scored by a blinded observer for
changes in the joint architecture using our previously
described grading system [20,24] as follows: 0 = normal,
1 = minimal synovitis and bone erosion limited to dis-
crete foci, 2 = extensive synovial hyperplasia and some
destruction of segments cartilage and bone and 3 =
complete destruction of the joint architecture.
Fluorescence optical imaging in vivo
Anti-mouse E-selectin mAb (MES-1) was purified from
a hybridoma cell line (a kind gift from Dr Derek Brown,
UCB Celltech, Slough, UK) and conjugated to DyLight
750 near-infrared (NIR) fluorophore according to the
manufacturer’s instructions (Thermo Scientific, Lough-
borough, UK). For imaging studies, mice were anaesthe-
tised with a mixture of isofluorane and oxygen prior to
intravenous injection of 5 μg of antibody. Optical ima-
ging was performed using a Kodak FX Pro multispectral
fluorescence reflectance imaging device (Carestream
M o l e c u l a rI m a g i n g ,R o c h e s t e r ,N Y ,U S A ) .F i l t e r sf o r
excitation and emission were set to 730 nm and 770
nm, respectively. An identical imaging protocol (expo-
sure time 60 seconds, 4× binning, F-stop 2.51, field of
view 158.5, focal plane 9.4 mm) was maintained for all
images as previously described [22].
Images were analysed by a blinded observer using the
Kodak Molecular Imaging version 5.0 software program
(Carestream Health, Rochester, NY, USA). A region of
interest (ROI) created by an automated tool was deter-
mined around the inflamed or control paw. Mean ROI
signal intensities are expressed as arbitrary fluorescent
signal intensity units. Fluorescence greyscale images
were artificially coloured for depiction purposes accord-
ing a colour scale set to the highest and lowest levels of
mean fluorescence intensity (MFI) (with red and purple
indicating maximum and minimum light intensity,
respectively). The fluorescence images were coregistered
onto X-ray images taken concurrently.
Statistical analyses
The data were analysed using GraphPad Prism version
5.01 software (GraphPad Software, Inc, San Diego, CA,
USA) using one-way analysis of variance (ANOVA) or
two-way ANOVA as appropriate. Histological data were
analysed by Χ
2 test for trends.
Results
Treatment of CIA with RB200 dose-dependently inhib-
ited the increase in clinical score (Figure 1a) and paw
swelling (Figure 1b). The mice were treated intraperito-
neally on the day of disease onset (day 1) and then on
d a y s4a n d7o fd i s e a s e .R B 2 0 0a tad o s eo f0 . 1m g / k g
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Figure 1 Dose-dependent effect of RB200 in collagen-induced arthritis. Following the onset of arthritis induced by bovine collagen, mice
were treated intraperitoneally on the day of disease onset (day 1) and then on days 4 and 7 of disease with RB200 at a dose of 0.1 mg/kg (n =
6), 1 mg/kg (n = 8) or 10 mg/kg (n = 8). Control mice received an equivalent volume of PBS intraperitoneally (n = 6). (a) The increase in clinical
score was assessed over a 10-day period, and the data are presented as means ± SEM compared to day 1 of arthritis. (b) Paw swelling was
measured with callipers, and data are means ± SEM of both hind paws expressed expressing the difference from baseline (in millimetres). The
data were derived from a representative experiment and analysed using two-way analysis of variance vs PBS-treated mice. ns = not significant;
***P < 0.001.
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significant benefit (P < 0.001 vs PBS for both paw swel-
ling and change in clinical score). On day 10 of estab-
lished disease, the mean increase in clinical score ±
SEM from day 1 of arthritis in mice treated with either
PBS or RB200 at 0.1, 1 and 10 mg/kg were 2.17 ± 0.54,
2.00 ± 0.73, 0.88 ± 0.74 and 1.14 ± 0.51, respectively
( F i g u r e1 a ) .T h e r ew a sa l s oar e d u c t i o ni nh i n dp a w
swelling in RB200-treated mice (Figure 1b).
Mouse paws were taken on day 10 of arthritis, and
frozen sections were cut and stained with anti-CD31
antibody. For each mouse, the metatarsal-tarsus joints of
both paws were examined, and representative images
from RB200- and PBS-treated mice are shown in Figures
2a through 2d. Joint sections of PBS-treated mice
showed high numbers of infiltrating cells in the inflamed
synovium, together with invasion and erosion of bone by
the synovium, associated with marked CD31 expression.
In contrast, joints from mice treated with 1 or 10 mg/kg
RB200 were relatively protected, with generally normal
appearance, well-preserved joint architecture and rela-
tively few CD31-positive blood vessels. In addition, an
overall subjective score between 0 and 3 was used to
grade CD31-immunopositive staining. Analysis of mean
scores for each treatment group showed there was a sig-
nificant reduction in CD31 immunopositivity in mice
treated with 10 mg/kg RB200 (P < 0.01) (Figure 2e).
Importantly, when a low dose of RB200 was combined
with a suboptimal dose of the TNFa inhibitor etaner-
cept (also given on days 1, 4 and 7 of arthritis), a
marked beneficial response was observed, with the com-
bination of 0.5 mg/kg RB200 and 1 mg/kg etanercept
having a marked effect on both measures of disease
activity in CIA (Figure 3). In this experiment, 0.5 mg/kg
RB200 alone had no effect on paw swelling (P >0 . 0 5v s
PBS-treated mice) and only a modest effect on clinical
score (P < 0.01), whereas 10 mg/kg RB200 significantly,
albeit not completely, reduced both parameters, in
agreement with the experiment illustrated in Figure 1.
Similarly, 1 mg/kg etanercept alone partially reduced
clinical score and paw swelling (P < 0.001) (Figure 3). In
contrast, the combination of low doses of RB200 and
etanercept was significantly different from either low-
dose etanercept alone (P <0 . 0 0 1f o rb o t hc l i n i c a ls c o r e
and paw swelling) or low-dose RB200 alone (P < 0.001
for both clinical score and paw swelling). The effective-
ness of the combination of 0.5 mg/kg RB200 and 1 mg/
kg etanercept was comparable to that seen with the
optimal dose of etanercept (5 mg/kg).
We further applied in vivo optical imaging to investi-
gate the effect of RB200. Figure 4 demonstrates repre-
sentative examples of fluorescence imaging with NIR
dye-labelled anti-E-selectin antibody for representative
mice. The images were coregistered with plain digital X-
rays of arthritic paws. E-selectin-specific fluorescent sig-
nals were detected in both hind paws of animals with
CIA (PBS-treated), but not in healthy (nonarthritic)
mice. Fluorescent signals were also visible in the
arthritic paws of mice that received low-dose etanercept
alone or low-dose RB200 alone. These data further
demonstrate that the combination of low-dose etaner-
cept and RB200 has a marked effect in decreasing the
E-selectin-targeted signal in animals with arthritis com-
pared with either treatment on its own. Although both
low-dose etanercept (1 mg/kg) and RB200 (0.5 mg/kg)
Figure 2 RB200 reduces synovial vascularity in collagen-
induced arthritis. Following the onset of arthritis induced by
bovine collagen, mice were treated intraperitoneally on the day of
disease onset (day 1) and then on days 4 and 7 of disease with
RB200 at a dose of 0.1 mg/kg (n = 6), 1 mg/kg (n = 8) or 10 mg/kg
(n = 8). Control mice received an equivalent volume of PBS
intraperitoneally (n = 6). Representative CD31-stained sections from
the first metatarsal joints of mice are shown. (a) PBS treatment. (b)
0.1 mg/kg RB200. (c) 1 mg/kg RB200. (d) 10 mg/kg RB200. (e)
CD31-stained sections were scored subjectively in a blinded fashion.
Scale bars are indicated. The criteria assessed included proximity of
positive staining to the joint, strength of immunopositive staining
and overall status of joint architecture. Statistical analyses were
carried out using one-way analysis of variance vs PBS-treated mice.
**P < 0.01.
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Page 5 of 13had some overall therapeutic efficacy, it was only with
combination treatment that there was complete abroga-
tion of fluorescent signal.
Quantification of MFI over 24 hours in the different
treatment groups is shown in Figure 5. For the purposes
of clarity, the MFI signal returned from animals treated
with either high-dose etanercept or RB200 are not
included in Figure 5a but are included in Figure 5b.
These data show that combination treatment returned
the anti-E-selectin MFI to the levels seen in healthy ani-
mals that were not immunised against CIA (no signifi-
cant difference by two-way ANOVA) (Figure 5a). Indeed
the effect of combination treatment was significantly dif-
ferent from that seen with either low-dose etanercept
alone (P < 0.01 by two-way ANOVA) or low-dose
RB200 alone (P < 0.001 by two-way ANOVA). In a
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Figure 3 Additive effect of low-dose etanercept and RB200 in collagen-induced arthritis. Following the onset of arthritis induced by
bovine collagen, mice were treated intraperitoneally on the day of disease onset (day 1) and then on days 4 and 7 of disease with RB200 at a
dose of 0.5 mg/kg (n = 6) or 10 mg/kg (n = 8) or with a combination of RB200 0.5 mg/kg and etanercept 1 mg/kg (n = 6). Control mice
received 5 mg/kg etanercept (n = 6) or 1 mg/kg etanercept (n = 7) or equivalent volumes of PBS (n = 7) intraperitoneally. (a) The increase in
clinical score was assessed over a 10-day period, and data are presented as means ± SEM compared to day 1 of arthritis. (b) Paw swelling was
measured with callipers, and data are presented as means ± SEM of both hind paws expressed as the difference from baseline (in millimetres).
The data were derived from a representative experiment and analysed using two-way analysis of variance vs PBS-treated mice. ns = not
significant; **P < 0.01; ***P < 0.001.
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Page 6 of 13Figure 4 In vivo E-selectin-targeted fluorescence imaging in collagen-induced arthritis following treatment with low dose etanercept
and/or RB200. Following the onset of arthritis induced by bovine collagen, mice were treated intraperitoneally on the day of disease onset
(day 1) and then on days 4 and 7 of disease with RB200 at a dose of 0.5 mg/kg or 1 mg/kg etanercept or with a combination of 0.5 mg/kg
RB200 and 1 mg/kg etanercept. Control mice received equivalent volumes of PBS intraperitoneally. For imaging, mice were injected
intravenously with near-infrared dye-labelled anti-E-selectin antibody (5 μg in 200 μl). Images were obtained eight hours after injection of the
dye-antibody conjugate. Left panels show representative fluorescent images obtained after application of a colour wheel to depict signal
intensity. Right panels show corresponding images coregistered with X-rays after subtraction of background fluorescence.
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Figure 5 Additive effects of low-dose etanercept and RB200 on E-selectin-targeted in vivo fluorescent imaging in collagen-induced
arthritis. Following the onset of arthritis induced by bovine collagen, mice were treated intraperitoneally on the day of disease onset (day 1)
and then on days 4 and 7 of disease with RB200 at a dose of 0.5 mg/kg (n = 6) or 10 mg/kg (n = 8) or with a combination of RB200 0.5 mg/kg
and etanercept 1 mg/kg (n = 6). Control mice received 5 mg/kg etanercept (n = 6), 1 mg/kg etanercept (n = 7) or equivalent volumes of PBS (n
= 7) intraperitoneally. For imaging, mice were injected intravenously with near-infrared dye-labelled anti-E-selectin antibody (5 μg in 200 μl).
Images were obtained 2, 8 and 24 hours after injection of the dye-antibody conjugate. (a) The results are expressed in arbitrary units (au) of
mean fluorescence intensity (MFI) ± SEM for both paws and were analysed using two-way analysis of variance (ANOVA) vs PBS-treated mice. ns
= not significant; ***P < 0.001. For clarity, data derived from animals treated with 10 mg/kg RB200 or 5 mg/kg etanercept were omitted. (b)
Data from a representative experiment are presented and expressed in arbitrary units (au) of mean fluorescence intensity (MFI) ± SEM for
individual paws eight hours after injection of the dye-antibody conjugate. They were analysed using one-way ANOVA vs PBS-treated mice. ns =
not significant; *P < 0.05; **P < 0.01; ***P < 0.001.
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geted fluorescence imaging is able to detect subclinical
levels of fluorescence in animals with a clinical score of
0 [22]. Here combination therapy involving low-dose
RB200 plus low-dose etanercept abrogated fluorescent
signal in all imaged paws to levels seen in healthy con-
trols, whereas following treatment with either high-dose
RB200 or etanercept, increased signal levels were evi-
dent in some of the paws (Figure 5b).
These data are supported by histological findings.
Using serial sections stained with either haematoxylin
and eosin or toluidine blue, we evaluated tibiotarsal
joints for signs of synovitis and erosive changes to bone
and cartilage. There were was a dose-dependent effect
of both RB200 alone and etanercept alone on joint
architecture, with progressively fewer severely destroyed
joints and more joints with mild or moderate destruc-
tion (Figure 6). However, the most pronounced effect
was observed when the combination treatment was
used, with 64% joints appearing normal (score 0; P <
0.001 vs untreated by Chi squared test for trend) com-
pared to 0% in mice that received low-dose RB200 alone
(P > 0.05 vs untreated and P < 0.001 vs combination
treatment) and 0% in mice treated with low-dose etaner-
cept alone (P < 0.05 vs untreated and P <0 . 0 1v sc o m -
bination treatment). Indeed the combination treatment
was even more effective than high-dose etanercept alone
(P < 0.05 vs combination treatment), highlighting the
effectiveness of combined pan-EGFR and TNFa-targeted
treatment in promoting joint protection.
Discussion
Anti-HER2 antibody trastuzumab has revolutionised the
treatment of patients with EGFR-positive breast cancer,
and agents targeting EGFR/HER1 are in use for colorec-
tal cancer therapy as well as for head and neck cancer.
Interestingly, researchers in a number of studies have
suggested that the family of EGF ligands and receptors
may have a role in the development of RA. For example,
expression of one of the primary ligands for EGFR/
HER1, TGF-a, is increased at both the mRNA and pro-
tein levels in RA synovium [11]. High levels of another
EGFR ligand, EGF, in RA synovial fluids have also been
demonstrated. However, researchers in another study
reported increased expression of AR, but not EGF, ERG,
EPG, BTC, NRG1 or HB-EGF, at the mRNA level in RA
compared to OA tissue. However, the reason for the
discrepancy between this report and other studies is
unclear [15]. Expression of HER2/ErbB2 in the syno-
vium of RA patients has been described further [11,12].
A treatment modality targeting EGFRs might therefore
be an attractive option in immunotherapy for RA.
RB200 is a heterodimer of the HER1/ErbB1 and
HER3/ErbB3 ECD [18,25]. This prototypical bispecific
ligand trap binds HER1/ErbB1 and HER3/ErbB3 ligands,
inhibits proliferation of a broad spectrum of cultured
cancer cells and suppresses growth of tumour xenografts
i nm o u s em o d e l s[ 1 8 ] .T h ee f f i c a c yo fR B 2 0 0h a sb e e n
Figure 6 A combination of low-dose etanercept and RB200
results in normalisation of joint architecture in collagen-
induced arthritis. To assess damage to cartilage and joints, we
stained serial sections of hind feet (4 μm) with (a) haematoxylin and
eosin or (b) toluidine blue. Tibiotarsal joint sections from animals
representing the median score for each group are shown. Bars =
100 μm. (c) Percentage of sections exhibiting normal appearance
(score 0), minimal synovitis and bone erosion (score 1), extensive
synovial hyperplasia and some destruction of cartilage and bone
(score 2), and complete destruction of the joint architecture (score
3). Data are derived from 9 to 14 sections per group.
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inhibited EGF- and NRG1-b1-stimulated tyrosine
phosphorylation of HER1, HER2 and HER3 and also
showed potency in cell proliferation assays [18]. In
addition, RB200 has been shown to inhibit tumour
growth in vivo in two human tumour xenograft (epi-
dermoid carcinoma and non-small cell lung cancer)
nude mouse models [18]. Thus, in contrast to antibo-
dies such as trastuzumab, RB200 has the potential to
inhibit signalling by multiple EGFR ligands. In this
study, we examined the effect of RB200 on established
CIA, which has been widely used for in vivo testing of
candidate therapeutics for RA, such as TNFa inhibi-
tors [26,27] and inhibitors of angiogenesis [23,28,29].
Moreover, we have previously reported that adenoviral
delivery of the human EGFR family inhibitor herstatin
significantly abrogated murine CIA [20], demonstrating
that by blocking signalling downstream of HER2/
ErbB2, HER3/ErbB3 was effective in CIA. In the cur-
rent study, administration of RB200 produced a signifi-
cant dose-dependent reduction in disease severity in
CIA. Interestingly, RB200 showed effective therapeutic
activity at doses as low as 1 mg/kg when administered
three times in the 10-day period of arthritis. Indeed 1
mg/kg was not significantly different from 10 mg/kg
(by two-way ANOVA), and higher doses of RB200 up
to 15 mg/kg were no more effective (not shown). EGF
has been reported to promote angiogenesis [30,31],
and there was also a significant reduction of CD31-
immunopositive staining in RB200-treated mice,
reflecting a reduction in synovial vessels. In compari-
son to controls, there was also normalisation of joint
architecture in arthritic mice treated with RB200.
T h e s ed a t as u g g e s tt h a ti n h i bition of EGFR-mediated
responses is of potential use for the treatment of RA.
The efficacy of combination treatment with low-dose
etanercept and RB200 is of potential interest. A signifi-
cant proportion of patients with RA do not respond to
TNFa blockade, and therefore there is a compelling
need to continue identification of alternative therapeutic
strategies for chronic inflammatory diseases such as RA.
Nonetheless, biological therapies, particularly those tar-
geting TNFa, are an undoubted success in RA, and
hence an approach combining TNFa inhibition with, for
example, an inhibitor of angiogenesis or with an inhibi-
tor of EGFR-induced events might be useful. Moreover,
targeting such separate mechanistic pathways could be
beneficial, unlike the combination of targeting IL-1 and
TNFa, which has been shown to be proinfective [25]. In
the present report, we demonstrate that low doses of
the TNFa inhibitor etanercept plus RB200, though only
modestly effective alone, completely abolished CIA to
levels comparable to those observed following treatment
with an optimal dose of etanercept.
We have also previously described the use of fluores-
cently labelled mAb against E-selectin to localise
endothelial activation in inflamed tissues in vivo and
have found this approach to be a sensitive, specific and
quantifiable molecular imaging technique in CIA [22].
The combination of low doses of etanercept and RB200
resulted in complete abrogation of E-selectin-targeted
fluorescent signal to levels seen in healthy controls and
was more effective than 5 mg/kg etanercept. In fact,
mice treated with 5 mg/kg etanercept displayed greater
variability of MFI values, implying that disease activity
may not have been completely abolished. We have pre-
v i o u s l ys h o w nad e g r e eo ff l u o r e s c e n ts i g n a li nm o u s e
paws that had been given a clinical score of 0, suggest-
i n gt h a tf l u o r e s c e n c ei m a g i n gm a yb em o r es e n s i t i v e
than conventional scoring [22]. Imaging of mice treated
with 5 mg/kg etanercept for 2 to 24 hours did in fact
reveal that the MFI readings were significantly different
(P < 0.01) from those in nonarthritic mice (not shown),
whereas MFI readings for mice treated with etanercept
plus RB200 were not significantly different from nonar-
thritic mice but lower than those treated with either
low-dose etanercept alone (P <0 . 0 1b yt w o - w a y
ANOVA) or low-dose RB200 alone (P < 0.001 by two-
way ANOVA). The in vivo fluorescence imaging data
are supported by observations of normalised joint archi-
tecture in animals treated with etanercept plus RB200.
Our findings substantiate the hypothesis that combi-
nation treatment with low doses of etanercept and
RB200 has a significant beneficial effect in CIA,
although there are a number of shortcomings of this
study, the most notable being the absence of mechanism
of action studies to elucidate the mode of action of
RB200 in CIA. In terms of a potential in vivo mechan-
ism of action of RB200, angiogenesis is a key feature of
RA [32], and indeed EGF has been reported to promote
angiogenesis [30,31,33], in part through production of
proangiogenic factors such as VEGF, IL-8 and basic
fibroblast growth factor [13,30,34,35]. Direct angiogenic
effects have also been demonstrated in human microvas-
cular endothelium in response to EGF or TGF-a
[36-38]. Other EGFR ligands, such as NRG1-b3, have
been reported to promote angiogenesis [39], and target-
ing EGFRs, alone or in combination with VEGF inhibi-
tion, has been shown to reduce angiogenesis in in vivo
models [38,40,41]. Activation of EGFR signalling may
also contribute to synovial hyperplasia in CIA, which is
also a major pathological feature of RA that precedes
clinical presentation and prevails throughout the disease
[31]. This is suggested by a report that trastuzumab,
which binds the HER2/ErbB2 receptor, inhibits RA
synovial cell growth [12]. RB200 has the potential to
inhibit responses to multiple EGFR ligands in CIA.
Although inhibition of synovial angiogenesis or
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study, which is clearly a limitation in terms of under-
standing a possible in vivo mode of action, studies asses-
sing whether synovial cell responses might be affected
by RB200 are in progress. However, inhibition of syno-
vial angiogenesis by RB200 could be implicated by the
reduction in CD31-positive blood vessels, which we
have demonstrated in CIA. Furthermore, EGF, when
combined with proinflammatory mediators such as
TNFa and IL-1, has been shown to increase expression
by fibroblasts of matrix metalloproteinases (MMPs) such
as MMP-1, MMP-3 and MMP-13 [42,43] and to upre-
gulate fibroblast proliferation [44]. Moreover, these
responses were abrogated by a small-molecule inhibitor
of HER2/ErbB2. It would be useful to examine whether
RB200 modulates RA fibroblast responses in vitro,i n
particular by assessing MMP expression, as this would
provide invaluable insight into how RB200 might affect
CIA.
It is also unclear which of the many EGFR ligands
RB200 inhibits in CIA. In addition to the presence of
EGF in RA synovium [6], expression of TGF-a and AR
has been described in RA [11,15], and RB200 has been
reported to bind to all of these ligands [18]. Interest-
ingly, the pan-EGFR activity of RRB200 suggests that
this molecule could offer additional benefit over
approved treatments such as trastuzumab (a mAb that
targets HER2) [45], cetuximab and panitumumab (anti-
EGFR/HER1 antibodies), as well as inhibitors such erlo-
tinib, lapatinib and gefitinib [46-48]. Resistance to these
agents can occur as a result of coexpression and ligand
activation of other HER family members [49-51].
Furthermore, homodimerisation and heterodimerisation
among members of the ErbB receptors is known to
occur [10], hence therapies directed against a single
HER receptor are likely to be less effective [7], suggest-
ing that agents such as RB200, which target multiple
receptors, are desirable. Indeed the pleiotropic effects
mediated by ligation of the EGFR family (for example,
angiogenesis, inflammation and synovial invasion) and
the expression of multiple EGFR ligands in RA suggest
that pan-EGFR blockade is likely to have a broad benefi-
cial effect in arthritis.
Conclusions
The studies described in this report demonstrate that
the potent human EGFR HER1/HER3 ECD heterodi-
mer RB200 has a significant abrogating effect in a
mouse model of RA, namely, CIA. A recent case report
described a patient with long-standing RA who had
previously been treated with rituximab and adalimu-
mab. This patient experienced a significant reduction
in joint pain during treatment with anti-EGFR/HER1
antibody cetuximab for head and neck cancer [52].
Together with our data in murine CIA, these findings
highlight the usefulness of targeting the EGFR family
in RA.
However, cellular heterogeneity, redundancy of mole-
cular pathways and effects of the microenvironment all
likely contribute to the disease heterogeneity seen in
CIA. This makes it unlikely that therapy directed at one
abnormally activated signalling pathway, such as that
downstream of EGFR activation, is likely to be sufficient
[53]. Therefore, combined blockade of functionally
linked and relevant multiple targets has become an
attractive therapeutic strategy, particularly given the
increased risk of infection associated with some classes
of biologicals [54-56]. Combination of RB200 with the
TNFa blocker etanercept resulted in complete abroga-
tion of arthritis, suggesting that HER-targeted therapies
developed for the treatment of cancer may also be effec-
tive in RA.
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